This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | MicrobiomeTrials
← Back to trials NCT06398418
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-08-01Est. Completion: 2027-04-30
Enrollment target: 33 participantsLocations Sarah Cannon Research Institute, Denver, Colorado, United States Sarah Cannon Research Institute, Nashville, Tennessee, United States Other microbiome trials you might be interested in Advanced Cancer Metastatic Cancer Solid Tumor Melanoma Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Anaplastic Thyroid Cancer (ATC)
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with ad…
Los Angeles, United States Est. completion Apr 1, 2028
Soft Tissue Sarcoma (STS)
Breast Neoplasms
This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combinati…
Houston, United States Est. completion Sep 1, 2030
Very Rare Tumors Very Rare Cancers Other Solid Tumors Solid Tumor Pediatric Rare Tumors
Background:
All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewe…
Bethesda, United States Est. completion Apr 1, 2035